T1	intervention 31 41	toremifene
T2	control 63 73	exemestane
T3	eligibility 146 222	postmenopausal women with hormone receptor-positive metastatic breast cancer
T4	outcome-Measure 684 711	clinical benefit rate (CBR)
T6	total-participants 865 867	91
T7	intervention-participants 946 948	46
T8	control-participants 962 964	45
T10	outcome 1402 1405	CBR
T11	intervention-participants 1369 1371	46
T12	control-participants 1386 1388	45
T13	iv-bin-percent 1407 1412	41.3%
T14	cv-bin-percent 1417 1422	26.7%
T16	iv-bin-percent 1440 1445	10.8%
T17	cv-bin-percent 1450 1454	2.2%
T18	outcome 1472 1474	OS
T21	outcome 1511 1514	PFS
T24	outcome 1772 1786	adverse events
T25	iv-bin-abs 1814 1815	3
T26	intervention-participants 1819 1821	43
T9	outcome 1435 1438	ORR
T5	outcome-Measure 743 772	objective response rate (ORR)
T15	outcome-Measure 774 805	progression-free survival (PFS)
T19	outcome-Measure 807 828	overall survival (OS)
T20	outcome-Measure 833 841	toxicity
